252.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$249.69
Aprire:
$250.64
Volume 24 ore:
458.61K
Relative Volume:
0.44
Capitalizzazione di mercato:
$35.89B
Reddito:
$5.02B
Utile/perdita netta:
$1.31B
Rapporto P/E:
28.31
EPS:
8.91
Flusso di cassa netto:
$1.56B
1 W Prestazione:
+3.03%
1M Prestazione:
+4.24%
6M Prestazione:
+4.47%
1 anno Prestazione:
+19.21%
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Confronta RMD con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RMD
Resmed Inc
|
252.20 | 35.89B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
ISRG
Intuitive Surgical Inc
|
557.08 | 197.97B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
173.45 | 49.82B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
ALC
Alcon Inc
|
87.79 | 42.51B | 9.93B | 1.12B | 1.58B | 2.25 |
![]()
BAX
Baxter International Inc
|
30.26 | 15.65B | 11.89B | -560.00M | 191.00M | -1.10 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-19 | Iniziato | Morgan Stanley | Overweight |
2025-01-16 | Iniziato | Goldman | Buy |
2025-01-10 | Iniziato | Piper Sandler | Neutral |
2024-12-13 | Iniziato | Stifel | Hold |
2024-09-24 | Iniziato | Robert W. Baird | Outperform |
2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
2024-09-04 | Downgrade | Needham | Buy → Hold |
2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2023-09-06 | Aggiornamento | Needham | Hold → Buy |
2023-09-05 | Downgrade | UBS | Buy → Neutral |
2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2023-05-23 | Iniziato | UBS | Buy |
2023-04-14 | Iniziato | Mizuho | Buy |
2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
2022-10-12 | Iniziato | Jefferies | Hold |
2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
2022-08-15 | Downgrade | CLSA | Buy → Outperform |
2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2022-04-06 | Iniziato | Wolfe Research | Outperform |
2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
2021-08-02 | Downgrade | CLSA | Outperform → Sell |
2021-08-02 | Downgrade | Needham | Buy → Hold |
2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
2021-06-22 | Iniziato | Robert W. Baird | Neutral |
2021-06-21 | Reiterato | Needham | Buy |
2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
2021-03-16 | Aggiornamento | Needham | Hold → Buy |
2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-02-03 | Iniziato | CLSA | Underperform |
2020-01-31 | Downgrade | UBS | Buy → Neutral |
2020-01-10 | Iniziato | Oppenheimer | Perform |
2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
2019-07-16 | Downgrade | UBS | Buy → Neutral |
2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
2019-01-25 | Downgrade | Goldman | Buy → Neutral |
2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed director Peter Farrell sells $494,640 in stock By Investing.com - Investing.com Nigeria
ResMed director Peter Farrell sells $494,640 in stock - Investing.com Australia
Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell? - MSN
ResMed Inc Director Proposes Sale of Common Shares - TipRanks
Successful Exits - University College Dublin
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed CFO Sells Shares - marketscreener.com
Resmed Inc Reports Decrease in CDI Issuance for May 2025 - TipRanks
ResMed CFO Executes Stock Sale Under Rule 10b5-1 Plan - TipRanks
Resmed Inc Officer Plans Sale of Common Stock - TipRanks
ResMed’s global general counsel Michael Rider sells $9,994 in shares By Investing.com - Investing.com South Africa
ResMed’s global general counsel Michael Rider sells $9,994 in shares - Investing.com
Dental Sleep Medicine Market Projected to Witness Massive GrowthResMed Inc., SomnoMed Limited - openPR.com
Citi raises ResMed stock price target to AUD45 citing strong EPS growth - Investing.com Nigeria
Here's why I invested MORE money in ResMed shares last week - MSN
There's Reason For Concern Over ResMed Inc.'s (NYSE:RMD) Price - simplywall.st
Sleep Apnea Oral Appliances MarketGlobal Forecast to 2030 with SomnoMed, Resmed, ProSomnus, DynaFlex, Vivos Therapeutics, and OpenAirway Leading - Yahoo Finance
ResMed Inc. Files Conflict Minerals Disclosure Report for 2024 - TipRanks
Actigraphy Devices Market Report 2025-2034 | Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape - GlobeNewswire Inc.
ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan - TipRanks
ResMed CFO Brett Sandercock sells $891,285 in stock By Investing.com - Investing.com South Africa
Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Chase Coleman, John Paulson, Polus Capital Management, VFC Corp (VFC), ResMed Inc (RMD), and More - Insider Monkey
ResMed CFO Brett Sandercock sells $891,285 in stock - Investing.com Australia
ResMed’s SWOT analysis: sleep tech giant faces growth challenges, new markets - Investing.com
ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Are Wall Street Analysts Bullish on ResMed Stock? - Inkl
Are Wall Street Analysts Bullish On ResMed Stock? - Barchart.com
Is it Worth Retaining ResMed Stock in Your Portfolio Now? - Nasdaq
Insider Sell: Witte De Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
Why Kogan, Monash IVF, OFX, and ResMed shares are falling today - MSN
Down 5%: What's going on with the ResMed share price? - MSN
RMD ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of ResMed Inc. Shareholders Who Lost Money - ACCESS Newswire
Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed - Yahoo Finance
Should you buy the dip in the ResMed share price? - MSN
ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved By Stocktwits - Investing.com India
ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved - MSN
Positive Phase 3 Trial Results for RMD's Sleep Apnea Treatment | - GuruFocus
ResMed (RMD) Faces Potential Market Challenges from New Sleep Apnea Treatment | RMD Stock News - GuruFocus
Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance
ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly - simplywall.st
Apnea Therapy Market Is Booming Worldwide 2025-2032 | ResMed Inc., Koninklijke Philips N.V. - openPR.com
Resmed (RMD) Partners with Rugby Tour to Promote Sleep Health | - GuruFocus
ResMed named Sleep Partner of the Qatar Airways British & Irish Lions Tour - TipRanks
Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 - The Spec
Patient Monitoring Stocks Q1 Teardown: ResMed (NYSE:RMD) Vs The Rest - Yahoo Finance
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):